Targeting angiogenesis in bladder cancer

Current Oncology Reports

Volumn 11, Issue 3, 2009, Pages 244-249

  Elfiky, Aymen A ^a   Rosenberg, Jonathan E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PAZOPANIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VINBLASTINE;

ANTIANGIOGENIC ACTIVITY; BLADDER CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DRUG TARGETING; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; PHARMACOGENOMICS; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65349189892     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0034-2     Document Type: Review

References (58)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-205; discussion 205-206.
3. Sonpavde G, Petrylak DP: Perioperative chemotherapy for bladder cancer. Crit Rev Oncol Hematol 2006, 57:133-144.
4. von der Maase H, Hansen SW, Roberts JT, et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
5. von der Maase H, Sengelov L, Roberts JT, et al.: Longterm survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608.
6. Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990, 50:6130-6138.
7. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial award lecture. Cancer Res 1986, 46:467-473.
8. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991, 64:327-336.
9. Crew JP, O'Brien T, Bradburn M, et al.: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997, 57:5281-5285.
10. O'Brien T, Cranston D, Fuggle S, et al.: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995, 55:510-513.
11. Allen LE, Maher PA: Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J Cell Physiol 1993, 155:368-375.
12. Nguyen M, Watanabe H, Budson AE, et al.: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993, 85:241-242.
13. Inoue K, Slaton JW, Karashima T, et al.: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000, 6:4866-4873.
14. Izawa JI, Slaton JW, Kedar D, et al.: Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001, 8:9-15.
15. Slaton JW, Millikan R, Inoue K, et al.: Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004, 171:570-574.
16. Bochner BH, Cote RJ, Weidner N, et al.: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995, 87:1603-1612.
17. Canoglu A, Gogus C, Beduk Y, et al.: Microvessel density as a prognostic marker in bladder carcinoma: Correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004, 36:401-405.
18. Dickinson AJ, Fox SB, Persad RA, et al.: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994, 74:762-766.
19. Dinney CP, Babkowski RC, Antelo M, et al.: Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol 1998, 160:1285-1290.
20. Goddard JC, Sutton CD, Furness PN, et al.: Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003, 9:2583-2586.
21. Jaeger TM, Weidner N, Chew K, et al.: Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995, 154:69-71.
22. Beecken WD, Engl T, Hofmann J, et al.: Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder. J Cell Mol Med 2005, 9:655-661.
23. Campbell SC, Volpert OV, Ivanovich M, Bouck NP: Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998, 58:1298-1304.
24. Dinney CP, Bielenberg DR, Perrotte P, et al.: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998, 58:808-814.
25. Tanaka Y, Kawamata H, Fujimoto K, Oyasu R: Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J Urol 1997, 157:683-688.
26. Crew JP, Fuggle S, Bicknell R, et al.: Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000, 82:161-166.
27. Yang CC, Chu KC, Yeh WM: The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004, 22:1-6.
28. Wu W, Shu X, Hovsepyan H, et al.: VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003, 22:3361-3370.
29. Bernardini S, Fauconnet S, Chabannes E, et al.: Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001, 166:1275-1279.
30. Inoue K, Kamada M, Slaton JW, et al.: The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002, 8:1863-1870.
31. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
32. Boucher Y, Kirkwood JM, Opacic D, et al.: Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991, 51:6691-6694.
33. Gutmann R, Leunig M, Feyh J, et al.: Interstitial hypertension in head and neck tumors in patients: Correlation with tumor size. Cancer Res 1992, 52:1993-1995.
34. Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
35. Shishido T, Yasoshima T, Denno R, et al.: Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 1998, 89:963-969.
36. Sweeney CJ, Miller KD, Sissons SE, et al.: The anti-angiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61:3369-3372.
37. Teicher BA, Holden SA, Ara G, et al.: Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. Int J Cancer 1995, 61:732-737.
38. Bellmunt J, von der Maase H, Mead GM, et al.: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/ cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study [abstract]. J Clin Oncol 2007, 25(18 Suppl):LBA5030.
39. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
40. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. J Clin Oncol 2005, 23(16 Suppl):2.
41. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
42. MAller KD, Wang M, Gralow J, et al.: E2100: a randomised phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology. Orlando, FL; May 13-17, 2005.
43. Sandler AB, Gray R, Brahmer J, et al.: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial'E4599. J Clin Oncol 2005, 23(16 Suppl):LBA4.
44. Osai WE, Ng CS, Pagliaro LC: Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs 2008, 19:427-429.
45. Xia G, Kumar SR, Hawes D, et al.: Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006, 175:1245-1252.
46. Inoue K, Slaton JW, Davis DW, et al.: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 2000, 6:2635-2643.
47. Davis DW, Inoue K, Dinney CPN, et al.: Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 2004, 64:4601-4610.
48. Posey JA, Ng TC, Yang B, et al.: A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003, 9:1323-1332.
49. Kane RC, Farrell AT, Saber H, et al.: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006, 12:7271-7278.
50. Pasche B: A new strategy in the war on renHl cell cancer: hitting multiple targets with limited collateral damage. JAMA 2006, 295:2537-2538.
51. Wilhelm SM, Carter C, Tang L, et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
52. Sridhar SS, Winquist E, Eisen A: A phase II study of first-line sorafenib (Bay 43-9006) in advanced or metastatic urothelial cancer. A trial of the PMH Phase II Consortium [abstract]. Proceedings of the 2008 Genitourinary Cancers Symposium. Alexandria, VA: American Society of Clinical Oncology; 2008. Abstract 340.
53. Dreicer R, Li H, Stein MN, et al.: Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2008, 26(15 Suppl):5083.
54. Gallagher DJ, Milowsky MI, Gerst SR, et al.: Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol 2007, 25(18 Suppl):5080.
55. Kim EJ, Jeong P, Quan C, et al.: Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer. Urology 2005, 65:70-75.
56. Krippl P, Langsenlehner U, Renner W, et al.: A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003, 106:468-471.
57. Garcia-Closas N, Malats N, Real FX, et al.: Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007, 3:e29.
58. Schneider BP, Wang M, Radovich M, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.